Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease
Ian A. Clark, Bryce Vissel
Biochemical Pharmacology (2013) Vol. 86, Iss. 7, pp. 862-871
Open Access | Times Cited: 22

Showing 22 citing articles:

Melatonin and inflammation—Story of a double‐edged blade
Rüdiger Hardeland
Journal of Pineal Research (2018) Vol. 65, Iss. 4
Open Access | Times Cited: 375
Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks
Rüdiger Hardeland
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1223-1223
Open Access | Times Cited: 284
Protecting the Melatonin Rhythm through Circadian Healthy Light Exposure
María‐Ángeles Bonmatí‐Carrión, Raquel Argüelles-Prieto, María José Martínez-Madrid, et al.
International Journal of Molecular Sciences (2014) Vol. 15, Iss. 12, pp. 23448-23500
Open Access | Times Cited: 195
Botanicals and Their Bioactive Phytochemicals for Women’s Health
Birgit M. Dietz, Atieh Hajirahimkhan, Tareisha L. Dunlap, et al.
Pharmacological Reviews (2016) Vol. 68, Iss. 4, pp. 1026-1073
Open Access | Times Cited: 182
Melatonin and brain inflammaging
Rüdiger Hardeland, Daniel P. Cardinali, Gregory M. Brown, et al.
Progress in Neurobiology (2015) Vol. 127-128, pp. 46-63
Open Access | Times Cited: 169
Melatonin and the pathologies of weakened or dysregulated circadian oscillators
Rüdiger Hardeland
Journal of Pineal Research (2016) Vol. 62, Iss. 1
Open Access | Times Cited: 107
Advances in non-dopaminergic treatments for Parkinson's disease
Sandy Stayte, Bryce Vissel
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 95
Inflammation-sleep interface in brain disease: TNF, insulin, orexin
Ian A. Clark, Bryce Vissel
Journal of Neuroinflammation (2014) Vol. 11, Iss. 1, pp. 51-51
Open Access | Times Cited: 87
Amyloid β: one of three danger‐associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease
Ian A. Clark, Bryce Vissel
British Journal of Pharmacology (2015) Vol. 172, Iss. 15, pp. 3714-3727
Open Access | Times Cited: 78
The meteorology of cytokine storms, and the clinical usefulness of this knowledge
Ian A. Clark, Bryce Vissel
Seminars in Immunopathology (2017) Vol. 39, Iss. 5, pp. 505-516
Open Access | Times Cited: 73
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 28
Insulin resistance, neuroinflammation, and Alzheimer’s disease
Dema Najem, Michelle Bamji‐Mirza, Nina Chang, et al.
Reviews in the Neurosciences (2014) Vol. 25, Iss. 4
Closed Access | Times Cited: 64
Ethanol extract of Astragali Radix and Salviae Miltiorrhizae Radix, Myelophil, exerts anti-amnesic effect in a mouse model of scopolamine-induced memory deficits
Jin‐Seok Lee, Hyeong-Geug Kim, Jongmin Han, et al.
Journal of Ethnopharmacology (2014) Vol. 153, Iss. 3, pp. 782-792
Closed Access | Times Cited: 40
Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
Tracey A. Ignatowski, Robert N. Spengler, Krishnan M. Dhandapani, et al.
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 679-697
Open Access | Times Cited: 36
Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α‐synuclein, amyloid‐β and insulin resistance in neurodegenerative diseases
Ian A. Clark, Bryce Vissel
British Journal of Pharmacology (2018) Vol. 175, Iss. 20, pp. 3859-3875
Open Access | Times Cited: 34
Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches
IA Clark, Bryce Vissel
Journal of Alzheimer s Disease (2021) Vol. 79, Iss. 3, pp. 931-948
Open Access | Times Cited: 18
High-Fructose Consumption Impairs the Redox System and Protein Quality Control in the Brain of Syrian Hamsters: Therapeutic Effects of Melatonin
Juan Carlos Bermejo-Millo, Marcela Rodrigues Moreira Guimarães, Beatriz de Luxán‐Delgado, et al.
Molecular Neurobiology (2018) Vol. 55, Iss. 10, pp. 7973-7986
Open Access | Times Cited: 22
Melatonin in Healthy Aging and Longevity
Rüdiger Hardeland
Healthy ageing and longevity (2017), pp. 209-242
Closed Access | Times Cited: 10
Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
Tracey A. Ignatowski, Robert N. Spengler, Edward Tobinick
CNS Drugs (2014) Vol. 28, Iss. 12, pp. 1207-1213
Open Access | Times Cited: 7
Phytochemicals in Clinical Studies: Current Perspective
Shashank Kumar, Deepak Kumar, Audesh Bhat, et al.
Springer eBooks (2018), pp. 471-511
Closed Access | Times Cited: 3
Circadian Disruption, Sleep Loss, and Low-Grade Inflammation
Rüdiger Hardeland
Research and Reviews on Healthcare Open Access Journal (2018) Vol. 1, Iss. 2
Open Access | Times Cited: 2
DMP in the putative promoter region of TLR9 in the superior temporal gyrus postmortem brain tissue in patients with Alzheimers disease.
Yu Sun, Qingqin S. Li
(2018) Vol. 03, Iss. 01
Closed Access
Page 1

Scroll to top